+

PE20120008A1 - Derivados de fenoxi bencenosulfonamida - Google Patents

Derivados de fenoxi bencenosulfonamida

Info

Publication number
PE20120008A1
PE20120008A1 PE2011001300A PE2011001300A PE20120008A1 PE 20120008 A1 PE20120008 A1 PE 20120008A1 PE 2011001300 A PE2011001300 A PE 2011001300A PE 2011001300 A PE2011001300 A PE 2011001300A PE 20120008 A1 PE20120008 A1 PE 20120008A1
Authority
PE
Peru
Prior art keywords
chloro
thiazol
halo
hydroxy
optionally substituted
Prior art date
Application number
PE2011001300A
Other languages
English (en)
Inventor
Serge Beaudoin
Michael Christopher Laufersweiler
Brian Edward Marron
David Simon Millan
David James Rawson
Steven Michael Reister
Kosuke Sasaki
Robert Ian Storer
Paul Anthony Stupple
Nigel Alan Swain
Christopher William West
Shulan Zhou
Christopher John Markworth
Original Assignee
Icagen Inc
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120008(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icagen Inc, Pfizer Ltd filed Critical Icagen Inc
Publication of PE20120008A1 publication Critical patent/PE20120008A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C07D263/50—Benzene-sulfonamido oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE SULFONAMIDA DE FORMULA (I) DONDE Z ES HET2 OPCIONALMENTE SUSTITUIDO CON HALO, CN, ALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS, EN DONDE HET2 ES UN HETEROCICLICO AROMATICO DE 5 O 6 MIEMBROS; Y1, Y2, Y3 E Y4 SON CADA UNO CH, CR1 O N, EN DONDE R1 ES HALO, AMINO, HIDROXI, ALQUILO(C1-C4), ENTRE OTROS; B ES FENILO O HET2 OPCIONALMENTE SUSTITUIDOS CON CN, HIDROXI, HALOALCOXI(C1-C4), ENTRE OTROS; X ESTA AUSENTE O ES -O-, METILENO, ETILENO, ENTRE OTROS; C ES CICLOALQUILO(C3-C8), HET1, FENILO O HET2 OPCIONALMENTE SUSTITUIDOS CON HALO, CN, HIDROXI, ENTRE OTROS, EN DONDE HET1 ES UN MONOCICLICO HETEROCICLICO DE 3 A 8 MIEMBROS. SON COMPUESTOS PREFERIDOS: 4-[2-(6-AMINOPIRIDIN-3-IL)-4-FLUOROFENOXI]-N-(5-CLORO-1,3-TIAZOL-2-IL)-3-CIANOBENCENOSULFONAMIDA; 5-CLORO-4-(4-CLORO-2-PIPERIDIN-4-ILFENOXI)-2-FLUORO-N-1,3-TIAZOL-4-ILBENCENOSULFONAMIDA; 4-[4-CLORO-2-(1H-PIRAZOL-4-IL)FENOXI]-3-CIANO-N-1,3-TIAZOL-2-ILBENCENOSULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL CANAL DE SODIO Nav1.7 SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR
PE2011001300A 2009-01-12 2010-01-06 Derivados de fenoxi bencenosulfonamida PE20120008A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14392009P 2009-01-12 2009-01-12
US24572609P 2009-09-25 2009-09-25
US25876009P 2009-11-06 2009-11-06

Publications (1)

Publication Number Publication Date
PE20120008A1 true PE20120008A1 (es) 2012-01-24

Family

ID=41818828

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001300A PE20120008A1 (es) 2009-01-12 2010-01-06 Derivados de fenoxi bencenosulfonamida
PE2014001348A PE20142099A1 (es) 2009-01-12 2010-01-06 Derivados de sulfonamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014001348A PE20142099A1 (es) 2009-01-12 2010-01-06 Derivados de sulfonamida

Country Status (42)

Country Link
US (3) US8153814B2 (es)
EP (1) EP2385938B1 (es)
JP (1) JP5053459B2 (es)
KR (1) KR101345497B1 (es)
CN (1) CN102348697B (es)
AP (1) AP2811A (es)
AR (1) AR075005A1 (es)
AU (1) AU2010204118B2 (es)
BR (1) BRPI1006128A2 (es)
CA (1) CA2747419C (es)
CL (1) CL2011001658A1 (es)
CO (1) CO6400220A2 (es)
CR (1) CR20110370A (es)
CU (1) CU24099B1 (es)
DK (1) DK2385938T3 (es)
DO (1) DOP2011000218A (es)
EA (1) EA020460B1 (es)
EC (1) ECSP11011198A (es)
ES (1) ES2536191T3 (es)
GE (1) GEP20135992B (es)
GT (1) GT201100195A (es)
HK (1) HK1161253A1 (es)
HN (1) HN2010000084A (es)
HR (1) HRP20150355T1 (es)
HU (1) HUE025013T2 (es)
IL (1) IL213517A (es)
MA (1) MA32965B1 (es)
MX (1) MX2011007424A (es)
MY (1) MY157017A (es)
NI (1) NI201100137A (es)
NZ (1) NZ593473A (es)
PE (2) PE20120008A1 (es)
PL (1) PL2385938T3 (es)
PT (1) PT2385938E (es)
RS (1) RS53941B1 (es)
SV (1) SV2011003970A (es)
TN (1) TN2011000316A1 (es)
TW (2) TWI494317B (es)
UA (1) UA105911C2 (es)
UY (1) UY32379A (es)
WO (1) WO2010079443A1 (es)
ZA (1) ZA201105530B (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009000851A1 (es) * 2008-04-08 2009-07-17 Gruenenthal Gmbh Compuestos derivados de sulfonamida; proceso de preparacion de estos; composicion farmaceutica que los comprende; uso en el tratamiento de dolores agudos, viscerales, neuropaticos o cronicos provocados por inflamacion, migraña, diabetes, problemas respiratorios, entre otros.
CU24099B1 (es) * 2009-01-12 2015-06-30 Pfizer Ltd Derivados de sulfonamida para el tratamiento del dolor
DE102009058280A1 (de) * 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
CA2789606A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues as opioid receptor agonists
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012004714A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
AR083023A1 (es) * 2010-09-17 2013-01-23 Purdue Pharma Lp Compuestos de piridina y una composicion farmaceutica que los comprende
SG191993A1 (en) 2011-01-18 2013-08-30 Amgen Inc Nav1.7 knockout mice and uses thereof
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
SG193513A1 (en) 2011-04-05 2013-10-30 Pfizer Ltd Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases
UY34171A (es) * 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
EP2731959B1 (en) 2011-07-13 2016-02-03 Pfizer Limited Enkephalin analogues
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
CA2852796A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
MX2014005297A (es) * 2011-10-31 2014-09-11 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
EP2800740A1 (en) * 2012-01-04 2014-11-12 Pfizer Limited N-aminosulfonyl benzamides
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013161928A1 (ja) * 2012-04-26 2013-10-31 塩野義製薬株式会社 オキサゾロトリアゾール誘導体およびそれらを含有する医薬組成物
WO2013161929A1 (ja) * 2012-04-26 2013-10-31 塩野義製薬株式会社 ピリジニルモルホリノン誘導体およびそれらを含有する医薬組成物
AR091112A1 (es) 2012-05-22 2015-01-14 Genentech Inc Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7
CA2874953A1 (en) 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
WO2014053965A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
WO2014053967A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
BR112015008508B1 (pt) * 2012-10-15 2022-06-07 In Therapeutics Compostos bloqueadores de canal de sódio, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar uma doença relacionada ao bloqueador de canal de sódio
CN104869992A (zh) 2012-10-26 2015-08-26 默沙东公司 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
CA2898679A1 (en) 2013-03-14 2014-09-25 Xenon Pharmaceuticals Inc. Substituted triazolopyridines and methods of use thereof
WO2014142221A1 (ja) 2013-03-14 2014-09-18 第一三共株式会社 呼吸器疾患用薬
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
ES2687481T3 (es) * 2013-03-15 2018-10-25 Chromocell Corporation Moduladores del canal de sodio para el tratamiento del dolor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
PE20160664A1 (es) 2013-06-27 2016-07-09 Pfizer Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
CA2919397C (en) * 2013-09-09 2021-05-18 Peloton Therapeutics, Inc. Aryl ethers as hif-2.alpha. inhibitors for the treatment of cancer
CN105611923B (zh) * 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3450428A1 (en) 2013-11-27 2019-03-06 Genentech, Inc. Substituted benzamides and methods of use thereof
US20170305857A1 (en) 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
US20170275275A1 (en) 2014-05-30 2017-09-28 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
CN114588157A (zh) 2014-07-17 2022-06-07 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
EP3193610A4 (en) * 2014-09-09 2018-04-04 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
ES2984026T3 (es) * 2015-06-16 2024-10-28 Atxa Therapeutics Ltd Antagonistas del receptor de tromboxano
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
RU2018115718A (ru) 2015-09-28 2019-10-28 Дженентек, Инк. Терапевтические соединения и способы их применения
KR20180080187A (ko) 2015-11-06 2018-07-11 다이이찌 산쿄 가부시키가이샤 디메톡시벤질기의 탈리 방법
BR112018009754B1 (pt) * 2015-11-13 2024-01-23 In Therapeutics Composto tendo função bloqueadora de canal de sódio, sua composição farmacêutica e seu uso
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
US10500205B2 (en) 2015-12-09 2019-12-10 Cadent Therapeutics, Inc. Thienopyrimidinone NMDA receptor modulators and uses thereof
PT3386591T (pt) 2015-12-09 2020-10-01 Cadent Therapeutics Inc Moduladores de recetores nmda heteroaromáticos e suas utilizações
WO2017098367A1 (en) 2015-12-10 2017-06-15 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
BR112018012327A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem
WO2017106409A1 (en) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
WO2017153952A1 (en) * 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
US10442778B2 (en) 2016-03-22 2019-10-15 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
CN106397425A (zh) * 2016-03-29 2017-02-15 广东环境保护工程职业学院 一种1,3,4-噻二唑类化合物及其制备方法
CN106397426A (zh) * 2016-03-29 2017-02-15 广东环境保护工程职业学院 一种1，3，4-噻二唑类化合物及其制备方法
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
CA3023465A1 (en) 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2017202376A1 (zh) * 2016-05-26 2017-11-30 南京明德新药研发股份有限公司 磺酰胺衍生物
MX388175B (es) 2016-10-17 2025-03-19 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
JP7022751B2 (ja) * 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
CN110446704B (zh) * 2017-03-23 2022-07-05 奥赖恩公司 用于制备磺酰胺结构化的激酶抑制剂的方法
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
JP2020532507A (ja) 2017-08-31 2020-11-12 ラクオリア創薬株式会社 Ｔｔｘ−ｓ遮断薬としてのビアリールオキシ誘導体
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2019241533A1 (en) 2018-06-13 2019-12-19 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
AU2019368147B2 (en) 2018-08-03 2024-05-30 Novartis Ag Heteroaromatic NMDA receptor modulators and uses thereof
WO2020047323A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
CN111285825B (zh) * 2018-12-10 2023-02-17 中国科学院上海药物研究所 一类苯磺酰胺取代的衍生物，其制法及其用途
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
WO2021247634A1 (en) * 2020-06-03 2021-12-09 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
CN114073698B (zh) * 2020-08-20 2023-03-31 山西泰睿鑫科技有限公司 一种止痛止痒药物组合物及其应用方法
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
KR20240171066A (ko) * 2022-01-28 2024-12-06 레벨 메디슨 인크 통증 치료용 제약 조성물
WO2024158653A2 (en) * 2023-01-26 2024-08-02 Merck Sharp & Dohme Llc N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background
CN116239543B (zh) * 2023-03-17 2024-09-10 河南省农业科学院植物保护研究所 N-取代三唑磺酰胺类化合物及其用途
CN116283740A (zh) * 2023-03-27 2023-06-23 上海添泽生物医药有限公司 一种药物中间体的合成方法
US12234205B1 (en) 2024-05-22 2025-02-25 King Saud University Sulfonylhydrazide derivatives as anticancer agents

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
DE3531919A1 (de) 1985-09-07 1987-03-19 Hoechst Ag Substituierte 2-phenyl-hexahydro-1,2,4-triazin-3,5-dione, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
DE3540654A1 (de) * 1985-11-13 1987-05-14 Schering Ag Phenoxy-substituierte ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0264538A (ja) 1988-08-31 1990-03-05 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE69206725T2 (de) 1991-09-10 1996-05-02 Zeneca Ltd Benzolsulfonamidderivate als 5-Lipoxygenasehemmer
GB2263635A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substitiuted triazoles as neurotensin antagonists
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) * 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
DK1041072T3 (da) * 1999-03-31 2003-11-10 Pfizer Prod Inc Dioxocyclopentylhydroxamsyrer
HN2000000074A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)-tetrahidropiran-3-carboxilicos.
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
WO2001008674A1 (fr) 1999-07-29 2001-02-08 Ono Pharmaceutical Co., Ltd. Derives de sulfonamide et remedes pour l'allodynie
EP1088819B1 (en) 1999-09-30 2005-06-15 Pfizer Products Inc. 6-azauracil derivatives as thyroid receptor ligands
WO2001056989A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001087293A1 (fr) 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Inhibiteurs de la ?-secretase
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
WO2003048159A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
WO2003059265A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP1536790A2 (en) 2002-08-09 2005-06-08 AstraZeneca AB Oxadiazoles as modulators of metabotropic glutamate receptor-5
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
NZ542920A (en) * 2003-03-24 2009-02-28 Actimis Pharmaceuticals Inc 2-Phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
WO2004103980A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005016267A2 (en) 2003-08-06 2005-02-24 Pfizer Products Inc. Oxazole compounds for the treatment of neurodegenerative disorders
AR045238A1 (es) * 2003-08-08 2005-10-19 Vertex Pharma Compuestos utiles como inhibidores de canales ionicos regulados por voltaje
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
CA2547212A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
AU2004299454A1 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-N-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
AU2005238296A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
EA011279B1 (ru) 2004-05-24 2009-02-27 Ф. Хоффманн-Ля Рош Аг (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
RU2416608C2 (ru) 2004-08-06 2011-04-20 Оцука Фармасьютикал Ко., Лтд. Ароматическое соединение
RU2409565C2 (ru) 2004-09-13 2011-01-20 Оно Фармасьютикал Ко., Лтд. Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
WO2006060762A2 (en) 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US20060173019A1 (en) 2005-01-14 2006-08-03 Solomon Ungashe Heteroaryl sulfonamides and CCR2
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
DE602006017694D1 (de) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
CN101287708B (zh) 2005-09-23 2012-02-29 辉瑞产品有限公司 用作细胞色素p450 3a4(cyp3a4)抑制剂的吡啶氨基磺酰基取代的苯甲酰胺
RU2008113210A (ru) * 2005-10-06 2009-10-10 Санофи-Авентис (Fr) 4-окси-n-[1, 3, 4]-тиадиазол-2-илбензолсульфонамиды, способы их получения и их применение в качестве фармацевтических средств
AU2006306367A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
AR058296A1 (es) 2005-12-09 2008-01-30 Kalypsys Inc Inhibidores de histona desacetilasa y composicion farmaceutica
WO2007076034A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
JP5089185B2 (ja) 2006-02-02 2012-12-05 大塚製薬株式会社 コラーゲン産生抑制剤。
WO2007092751A2 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
MX2008013114A (es) 2006-04-14 2008-10-21 Abbott Gmbh & Co Kg Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3.
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
EP2037905B1 (en) 2006-06-23 2013-05-01 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
CN101547908A (zh) 2006-10-05 2009-09-30 詹森药业有限公司 杂环衍生的金属蛋白酶抑制剂
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
WO2008050200A1 (en) 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
US9422235B2 (en) * 2006-12-19 2016-08-23 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
JP2008214222A (ja) 2007-03-01 2008-09-18 Tokyo Medical & Dental Univ フェノール誘導体及びその医薬用途
WO2008118758A1 (en) * 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
ES2323927B1 (es) 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
AU2008247102B2 (en) 2007-05-03 2011-11-24 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
JP2010526823A (ja) * 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009017719A2 (en) 2007-07-30 2009-02-05 Encysive Pharmaceuticals, Inc. Modulators of ccr9 receptor and methods of use thereof
US8119809B2 (en) 2007-11-16 2012-02-21 Rigel Pharmaceuticals, Inc. AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same
KR101626136B1 (ko) 2008-04-14 2016-06-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 플렉스트린 상동 도메인의 소분자 억제제 및 이의 사용방법
CN102036952A (zh) 2008-04-16 2011-04-27 比奥里波克斯公司 用作药物的双芳基化合物
CU24099B1 (es) * 2009-01-12 2015-06-30 Pfizer Ltd Derivados de sulfonamida para el tratamiento del dolor

Also Published As

Publication number Publication date
TWI419897B (zh) 2013-12-21
UA105911C2 (uk) 2014-07-10
MX2011007424A (es) 2011-08-12
CA2747419A1 (en) 2010-07-15
TW201422631A (zh) 2014-06-16
NI201100137A (es) 2011-11-02
CU24099B1 (es) 2015-06-30
RS53941B1 (en) 2015-08-31
CN102348697A (zh) 2012-02-08
HRP20150355T1 (hr) 2015-06-19
US8907101B2 (en) 2014-12-09
CO6400220A2 (es) 2012-03-15
AP2011005788A0 (en) 2011-08-31
US8541588B2 (en) 2013-09-24
UY32379A (es) 2010-08-31
SV2011003970A (es) 2012-01-03
HK1161253A1 (en) 2012-08-24
AU2010204118B2 (en) 2012-12-20
MA32965B1 (fr) 2012-01-02
US20120149679A1 (en) 2012-06-14
GEP20135992B (en) 2013-12-25
US20100197655A1 (en) 2010-08-05
CA2747419C (en) 2014-07-08
HUE025013T2 (hu) 2016-04-28
CL2011001658A1 (es) 2011-11-11
PL2385938T3 (pl) 2015-07-31
DK2385938T3 (en) 2015-04-27
KR20110104558A (ko) 2011-09-22
MY157017A (en) 2016-04-15
PT2385938E (pt) 2015-06-02
NZ593473A (en) 2013-02-22
TW201038586A (en) 2010-11-01
CR20110370A (es) 2011-07-21
CN102348697B (zh) 2014-12-10
JP2012515156A (ja) 2012-07-05
EA201170922A1 (ru) 2012-01-30
PE20142099A1 (es) 2014-12-13
HN2010000084A (es) 2011-12-05
TWI494317B (zh) 2015-08-01
ES2536191T3 (es) 2015-05-21
AU2010204118A1 (en) 2011-07-07
WO2010079443A1 (en) 2010-07-15
JP5053459B2 (ja) 2012-10-17
EA020460B1 (ru) 2014-11-28
AP2811A (en) 2013-12-31
ECSP11011198A (es) 2011-10-31
BRPI1006128A2 (pt) 2016-11-01
KR101345497B1 (ko) 2013-12-31
DOP2011000218A (es) 2011-10-15
GT201100195A (es) 2013-12-10
IL213517A0 (en) 2011-07-31
TN2011000316A1 (fr) 2012-12-17
IL213517A (en) 2015-11-30
US20130338111A1 (en) 2013-12-19
EP2385938A1 (en) 2011-11-16
AR075005A1 (es) 2011-03-02
CU20110145A7 (es) 2012-02-15
EP2385938B1 (en) 2015-03-04
ZA201105530B (en) 2012-12-27
US8153814B2 (en) 2012-04-10

Similar Documents

Publication Publication Date Title
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20131377A1 (es) Triazina-oxadiazoles
PE20090641A1 (es) Amidas heterociclicas
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20141375A1 (es) Activadores de glucoquinasa
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20091816A1 (es) Inhibidores de bace
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20100083A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20091925A1 (es) Derivados de indazol sustituidos con fenilo o benzodioxinilo
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
NZ594323A (en) Compositions and methods for inhibition of the jak pathway
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20091473A1 (es) Heterociclos como inhibidores de esteaoril-coa desaturasa
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
CR11470A (es) Compuestos organicos
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载